Detalhe da pesquisa
1.
Desmoglein-2 expression is an independent predictor of poor prognosis patients with multiple myeloma.
Mol Oncol
; 16(6): 1221-1240, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34245117
2.
Endothelial, pericyte and tumor cell expression in glioblastoma identifies fibroblast activation protein (FAP) as an excellent target for immunotherapy.
Clin Transl Immunology
; 9(10): e1191, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-33082953
3.
Desmoglein 2 promotes vasculogenic mimicry in melanoma and is associated with poor clinical outcome.
Oncotarget
; 7(29): 46492-46508, 2016 Jul 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-27340778